Physician profile
Michael W Becker
NPI 1689692691
$1,868.14
in general payments reported to CMS, 2019-2025
9 companies · $431 in 2025
The $431 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132 · 2022: $465 · 2023: $260 · 2024: $580 · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Gift: $825 · Food and Beverage: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Gift | $825.00 |
| Food and Beverage | $446.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sekisui Diagnostics LLC | $1,290.00 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $125.12 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.00 | 2024 | Iclusig |
| Incyte Corporation | $115.20 | 2025 | Niktimvo |
| Ptc Therapeutics, INC. | $107.31 | 2019 | |
| Celgene Corporation | $49.93 | 2024 | |
| Adaptive Biotechnologies Corporation | $30.83 | 2025 | Clonoseq |
| Kite Pharma, INC. | $24.75 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.